Supportive care
Phase 3Small molecule
BeiGeneSupportive care is one of 64 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
90 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Levophed
GGeneral Hospital of Ningxia Medical University
Approved
Glypressin
MMallinckrodt
Approved
Calciparine
BBaxter Healthcare Corporation
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Oraverse
LLife Extension Foundation Inc.
Phase 3
Lamisil
NovartisPhase 2
Northera
LundbeckPhase 2
Pitressin
AAultman Health Foundation
Phase 2
Arginine Vasopressin
SStanford University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Respiratory Distress Syndrome1 trial
COVID-191 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Supportive care. EMBL-EBI & Wellcome Sanger Institute.
- [4]